BCT with reference plasmas is appreciable but, on the basis of anticoagulant dose administration, was acceptable ( Fig 6) . The true prothrombin ratio may be below 1.8 (lower limit of therapeutic range) on 5 % of occasions when the recorded ratio is 2.1, and above 3.0 on 5 % of occasions when a ratio of 2.45 is recorded. These discrepancies appear to offer reasonable safety in anticoagulant administration, particularly as hemorrhage should not be expected at prothrombin ratios below 5.0 with the BCT. The lower limit of therapy has now also been raised from a ratio of 1.8 to 2.0 to provide a greater margin of safety from inadequate anticoagulant.
The second broad spectrum test in which quality control is being attempted is the partial thromboplastin time. This test is used both for oral anticoagulant and heparin control, but mainly as a screening test for defects of intrinsic blood coagulation such as occur in haemophilia and Christmas disease. The test suffers from the same lack of standardization and variability of results with different reagents as did the prothrombin time. Most of the reagents used in laboratories are commercially manufactured from animal tissues and many of these are grossly insensitive, that is, fail to pick out quite severe cases of hlemophilia. A standardized material was developed aiming to provide the maximum sensitivity to the human intrinsic clotting defect. A large batch has been laid down in lyophilized form at low temperatures as a primary standard. The standardized reagent has been provided to hospitals at home and abroad for a current quality control trial and for reference or routine work. A similar procedure has been adopted to the prothrombin time studies, with the supply of a set of three abnormal plasmas, standardized cephalin, other reagents required in the test and a recommended technique. One of the abnormal plasmas in the current trial represents a very slight clotting defect, the second a moderate coagulation defect, and the third quite severe. The results are being analyzed but all the hospitals appear to handle the standardized preparation with good results whereas the results with the commercial preparations are very variable. One widely available commercial reagent has consistently failed to pick out even the severe degree of clotting defect.
The British system for anticoagulant control has been until recently the only national system developed for the coordination of anticoagulant control. WHO therefore encouraged us to assist other countries to develop their own national systems for anticoagulant control, by provision of technical training, information and reagents. These reagents are currently sent from the WHO Centre at Manchester to laboratories in over 40 countries. They are represented in our quality control ofperformance exercises, but international participation in this programme has been strictly limited, so as to encourage but not to compete with the development of national systems in individual countries. 
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Quality Control in Blood Transfusion
The purpose of quality control in blood transfusion is to ensure the maximum safety of the blood donor and of the recipient of a transfusion, the term embracing the surveillance of the procedures involved at all stages, including the collection of blood, serological tests performed and the actual administration of the transfusion. The various points to be watched may be conveniently listed as follows: (1) Quality of taking and giving apparatus. (2) Technique by which the blood is collected. (3) Condition of blood in the container and the method ofstorage. (4) Organization of regional transfusion centres, including serology. (5) Organization of hospital blood bank including serology. (6) Reagent control. (7) Control of transfusion in hospital ward.
Apart from the quality of glassware and plastics used, the condition of the blood itself is most important. It must be free from hamolysis and bacterial infection, it must have been stored at a suitable temperature, while it must be of the blood group stated on the label. All serological investigations to determine blood groups and freedom from syphilis must have been performed with suitable reagents and by reliable techniques. All documentation in both regional transfusion centre and hospital laboratory must be correct and must be available for inspection should this be necessary. Finally, every care must be taken in the ward to see that the patient receives only the blood supplied for him. In this paper mention will be made only of proficiency testing of serology and briefly of reagent control. Although these are two different matters, they do overlap to some extent.
Proficiency Testing
Proficiency testing of laboratory serology is performed in various countries, including Australia, Canada, the United States of America and the United Kingdom. In the USA the College of American Pathologists undertook the first exercise in 1964 and now offer cell and serum samples for grouping in compatability testing at three-month intervals. A charge is made for this service, more than 1700 laboratories participating. In Canada, at approximately yearly intervals, serum samples are distributed to more than 80 laboratories who are asked to determine the blood group antibodies contained therein. In a recent Australian survey, serum samples and cells of known Rh groups were sent to over 100 laboratories, who were invited to detect and identify the Rh antibodies present in the sera. Again, the exercises are undertaken at approximately yearly intervals. All these exercises are organized centrally.
Proficiency Testing Schemefor England and Wales
In the United Kingdom, proficiency testing in blood group serology was first discussed in 1973 by directors of regional blood transfusion centres and a working party was set up to consider the matter. Discussions were held on the possibility of proficiency testing being undertaken centrally (either by a national quality control centre or by the Blood Group Reference Laboratory) or, alternatively, on a regional basis by regional blood transfusion centres. It was eventually decided that this type of work could be undertaken successfully only on a regional basis, for the following reasons:
(1) It was considered unlikely that any central laboratory could obtain sufficient supplies of red cells and of antibody-containing sera to allow proficiency testing in which all participating laboratories throughout the National Health Service would receive the same reagents.
(2) The handling ofmaterial by a central laboratory without its own donors must result in delay, so that red cell samples might be in a poor condition by the time they were received by hospital laboratories.
(3) It was felt that one of the most important aspects of quality control was to educate those whose standards were found to be too low. It would be difficult, ifnot insuperable, for a national centre to improve the standards of those whose blood group serology was consistently bad, whereas directors of regional transfusion centres were in a position to cooperate with pathologists in their areas, as they had done for many years, to provide help and training where this seemed to be necessary.
The Blood Group Reference Laboratory was asked to act as a central laboratory to test whether samples of cells and serum distributed by regional transfusion centres were satisfactory, and to introduce some degree of uniformity throughout the whole country. Hospitals were asked to test the material and report their findings as soon as possible. Regional transfusion centres would then send to each pathologist a summary of the results of all participating laboratories, anonymity being preserved, and each laboratory would be provided with comments on its own findings. It was considered important that not more than two weeks should elapse between distributing material and informing pathologists of the overall findings. It was felt that the exercises should be held every twelve weeks but, owing to shortage of red cells and sera, it was agreed that it might not be possible to hold them more often.
The present situation: Twelve out of fourteen regional transfusion centres in England and Wales are now involved in proficiency testing; the other two hope to join in as soon as they have sufficient staff and money. These twelve centres have started distributing cells and sera to their hospitals, usually asking participants to match all cell samples against all sera by techniques normally used for cross-matching, and to report their findings on a form supplied. In some cases participants are also asked to ABO-and Rhgroup one or more of the cell samples. Complete sets of the reagents are sent to the Blood Group Reference Laboratory where tests are also performed 'blind'. The Blood Group Reference Laboratory immediately telephones the director of each regional transfusion centre to discuss results obtained so that any discrepancies between those found at the centre and those demonstrated at the Blood Group Reference Laboratory can be studied and a cause sought.
Among the lessons learnt from the initial trials, it was clear that some antibodies being distributed were too weak for the purpose. This has been largely remedied, following advice from the Blood Group Reference Laboratory. Another important fact revealed is the variation in techniques used for compatibility testing. For instance, while most laboratories employ albumin techniques as part of their testing procedures, some have always employed enzyme methods; when these laboratories were asked, for the sake ofuniformity, to change to an albumin method, then results they obtained in proficiency studies became less satisfactory. Bearing in mind that the chief reason for proficiency testing is to maintain the highest degree of safety for the recipient of a transfusion, it will be clear that uniformity, although for certain reasons desirable, may be unobtainable and potentially dangerous. Regional variation in technique is something that can be dealt with only by regional transfusion centres, but not by any central laboratory.
Variations in technique have also led to difficulty of scoring results. Suggestions have been made for allocating scores for correct findings and for deductions to be made in the case of errors, the final scores to be explained as percentages. Nevertheless, problems of scoring where extra or different techniques are used have created difficulties which cannot be dealt with on a national basis. Indeed, while scoring of results can be helpful in giving hospital pathologists some indication of the efficiency of their own units compared with others in their Region, consultation which has developed between hospital laboratories and the transfusion centres has often been of greater value.
By testing all samples from regional transfusion centres 'blind', the Blood Group Reference Laboratory is now controlled. In addition, the Blood Group Reference Laboratory sends to all regional transfusion centres samples of sera known to contain antibody mixtures, directors being invited to test the material and report their findings back to the Blood Group Reference Laboratory. The results are examined at the Blood Group Reference Laboratory and directors of regional transfusion centres are told of the overall findings of other regions, anonymity being maintained. In this way, most regional transfusion centres, hospital laboratories and the Blood Group Reference Laboratory are now being controlled. During 1974 more than twenty-five exercises were organized throughout the country, and there were more than five hundred participants.
Reagent Control
The reliability of the reagents used has a considerable influence on the standard of serology reached in any laboratory. In some proficiency testing schemes participants are asked to state the names of the manufacturers and the batches of reagents used, so that any errors appearing in the results of a group of individuals may be shown to be dependent on some shortcoming of one or more of the reagents.
The Blood Group Reference Laboratory undertakes large-scale quality control of the reagents that it distributes but, equally, it provides an independent check on many grouping sera issued by regional transfusion centres or by overseas laboratories. Large numbers of tests are performed at all stages to ensure adequate potency and specificity of all sera issued. Specifications are laid down in Appendix XV of the British Pharmacopceia for ABOtyping and Rh-grouping sera as well as for anti-IgG. Care is taken at the Blood Group Reference Laboratory to see that reagents always reach, if not exceed, these standards. As an example, the antibodies that are excluded in anti-A grouping sera issued by the Blood Group Reference Laboratory are:
Anti-B, -M, -N, -S, -s, -Mia, -Vw, -P, -P1, -C, _CW, -c, -D, -E, -e, -Lea, -Le,b -Lua, -Lub, -K, -k, _Fya, -Fyb, _Jka, -Jkb, -Xga and -Wra. Anti-Gm (1), (2), (4), (5), (10), (11), (14) and (17). Anti-Inv (1) and (2).
Several members of staff of the Blood Group Reference Laboratory, directors of some of the regional blood transfusion centres and some hospital pathologists are members of the British Committee for Standards in Hwmatology's working party on the control and certification of blood grouping reagents. This working party has considered specifications, production of and standardization of rapid-typing Rh antisera, antiglobulin sera and various other reagents. It has also considered the possible need for and disadvantages of colouring blood grouping sera. Many of its findings have been made available to directors of regional blood transfusion centres and to the British Committee for Standards in Hematology in order that the quality of serological reagents can be kept at the highest possible level.
Professor H A F Dudley (Surgical Unit, St Mary's Hospital, London W2 INY) Audit and the Pathologist From time to time 1 have made some remarks about audit, and in consequence I have been asked to speaklargely from ignorance let it be admittedon this subject as it affects the pathologist. I shall limit my use of the term to studies of professional behaviour that may have a bearing on the proper delivery of care to patients. I am not directly concerned with the internal quality control of the pathological laboratory; rather I am trying, against the background of what the clinician in general and the surgeon in particular does or should do to make a good job of looking after patients, to ascertain how the pathologist is involved, what information, and in what form, he is committed to supply and how he may add to the richness of clinical surveillance.
